Document is current
Any future updates will be listed below
-
Authors
Greenough, Mark A. https://orcid.org/0000-0001-6767-0584
Lane, Darius J. R. https://orcid.org/0000-0001-8725-6903
Balez, Rachelle https://orcid.org/0000-0002-2787-7107
Anastacio, Helena Targa Dias https://orcid.org/0000-0002-1672-5378
Zeng, Zhiwen https://orcid.org/0000-0001-6398-8480
Ganio, Katherine https://orcid.org/0000-0001-7360-6466
McDevitt, Christopher A. https://orcid.org/0000-0003-1596-4841
Acevedo, Karla https://orcid.org/0000-0002-7996-3445
Belaidi, Abdel Ali https://orcid.org/0000-0003-0792-8728
Koistinaho, Jari https://orcid.org/0000-0001-6559-1153
Ooi, Lezanne https://orcid.org/0000-0001-9241-8268
Ayton, Scott https://orcid.org/0000-0002-3479-2427
Bush, Ashley I. https://orcid.org/0000-0001-8259-9069
- License Information
-
More Information
Article History
Received: 5 August 2021
Revised: 5 April 2022
Accepted: 5 April 2022
First Online: 21 April 2022
Competing interests
: AIB is a shareholder in Alterity Ltd, Cogstate Ltd and Mesoblast Ltd. He is a paid consultant for, and has a profit share interest in, Collaborative Medicinal Development Pty Ltd. He has received lecture fees from Biogen and Merck Sharp & Dohme P/L. No other authors have competing interests to declare.
: All human iPSC-experiments were conducted in accordance with the requirements of the University of Wollongong Human Ethics Research Committee (HE 13/299).
